{"title":"新产品简介(阿达木单抗(新适应症)、多卡韦单抗和莫洛马韦单抗、恩帕列嗪/利格列汀/盐酸二甲双胍(新组合)、埃那罗司他、非戈替尼、丙酸氟替卡松/富马酸福莫特罗/格隆吡隆(新组合,","authors":"","doi":"10.1358/dot.2021.57.1.3265445","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix,\",\"authors\":\"\",\"doi\":\"10.1358/dot.2021.57.1.3265445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2021.57.1.3265445\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.1.3265445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New product intros (adalimumab (new indication), docaravimab and miromavimab, empagliflozin/linagliptin/metformin hydrochloride (new combination), enarodustat, filgotinib, fluticasone propionate/formoterol fumarate/glycopyrronium (new combination), oliceridine, sofpironium bromide, tafasitamab-cxix,